DK1725655T3 - Cancerøse prostatastamceller - Google Patents
Cancerøse prostatastamcellerInfo
- Publication number
- DK1725655T3 DK1725655T3 DK05732870.0T DK05732870T DK1725655T3 DK 1725655 T3 DK1725655 T3 DK 1725655T3 DK 05732870 T DK05732870 T DK 05732870T DK 1725655 T3 DK1725655 T3 DK 1725655T3
- Authority
- DK
- Denmark
- Prior art keywords
- stem cells
- prostate stem
- cancerous prostate
- cancerous
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0406215.4A GB0406215D0 (en) | 2004-03-19 | 2004-03-19 | Prostate stem cell |
| PCT/GB2005/001142 WO2005089043A2 (fr) | 2004-03-19 | 2005-03-18 | Cellules souches de la prostate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1725655T3 true DK1725655T3 (da) | 2010-08-02 |
Family
ID=32118031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05732870.0T DK1725655T3 (da) | 2004-03-19 | 2005-03-18 | Cancerøse prostatastamceller |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8153421B2 (fr) |
| EP (2) | EP2009097A1 (fr) |
| JP (2) | JP5065885B2 (fr) |
| AT (1) | ATE465244T1 (fr) |
| AU (1) | AU2005222660B2 (fr) |
| CA (1) | CA2598879C (fr) |
| DE (1) | DE602005020750D1 (fr) |
| DK (1) | DK1725655T3 (fr) |
| ES (1) | ES2344706T3 (fr) |
| GB (2) | GB0406215D0 (fr) |
| WO (1) | WO2005089043A2 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0406215D0 (en) * | 2004-03-19 | 2004-04-21 | Procure Therapeutics Ltd | Prostate stem cell |
| CA3218940A1 (fr) * | 2004-11-12 | 2006-05-18 | Cambridge University Technical Services Ltd. | Procedes et moyens lies aux cellules souches cancereuses |
| US20090012024A1 (en) * | 2005-07-26 | 2009-01-08 | Procure Therapeutics Limited | Stem Cell Markers |
| JP5263756B2 (ja) | 2005-09-30 | 2013-08-14 | 国立大学法人 岡山大学 | 細胞の培養方法および細胞培養物 |
| GB0625041D0 (en) * | 2006-12-15 | 2007-01-24 | Procure Therapeutics Ltd | Prostate stem cell model |
| AU2007347689B2 (en) * | 2006-12-20 | 2013-08-15 | Novarx | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| KR101523698B1 (ko) | 2007-01-22 | 2015-05-29 | 마크로제닉스 웨스트 인코퍼레이티드 | 사람 암 줄기세포 |
| GB0701321D0 (en) * | 2007-01-24 | 2007-03-07 | Procure Therapeutics Ltd | Agent |
| GB0908934D0 (en) | 2009-05-26 | 2009-07-01 | Univ The West Of Scotland | Differentiation medium |
| GB0910751D0 (en) | 2009-06-23 | 2009-08-05 | Procure Therapeutics Ltd | Prostate cancer vaccine |
| WO2011158019A1 (fr) | 2010-06-16 | 2011-12-22 | Adjuvantix Limited | Vaccin à base de polypeptides |
| WO2012010904A1 (fr) | 2010-07-23 | 2012-01-26 | Procure Therapeutics Limited | Modèle mammifère utilisable en vue de l'amplification de cellules souches cancéreuses |
| WO2012026712A2 (fr) * | 2010-08-23 | 2012-03-01 | 주식회사 강스템홀딩스 | Composition pharmaceutique utilisée dans la prophylaxie ou le traitement de maladies immunitaires ou inflammatoires, contenant des cellules souches traitées par agoniste du nod2 ou un de leurs produits mis en culture |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| EP2611463A2 (fr) | 2010-09-03 | 2013-07-10 | Stem Centrx, Inc. | Identification et enrichissement de populations de cellules |
| GB201116702D0 (en) | 2011-09-28 | 2011-11-09 | Procure Therapeutics Ltd | Cell surface markers |
| US9506925B2 (en) | 2014-07-02 | 2016-11-29 | Dragon Victory Development Ltd. | Specific biomarker set for non-invasive diagnosis of liver cancer |
| WO2016003479A1 (fr) * | 2014-07-02 | 2016-01-07 | Dragon Victory Development Ltd. | Ensemble de biomarqueurs spécifiques pour le diagnostic non invasif d'un cancer du foie |
| US9885718B2 (en) | 2014-07-02 | 2018-02-06 | Dragon Victory Development Ltd. | Specific biomarker set for non-invasive diagnosis of liver cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (fr) | 1988-11-11 | 2004-09-29 | Medical Research Council | Clonage de séquences d'immunoglobulines de domaines variables. |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| JPH06509578A (ja) | 1991-07-26 | 1994-10-27 | ユニバーシティ・オブ・ロチェスター | 悪性細胞利用による癌治療法 |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5856136A (en) | 1996-07-03 | 1999-01-05 | Incyte Pharmaceuticals, Inc. | Human stem cell antigens |
| WO1998051805A1 (fr) | 1997-05-15 | 1998-11-19 | Abbott Laboratories | Reactifs et procedes utiles pour detecter des maladies de la prostate |
| KR100272659B1 (ko) | 1997-06-28 | 2000-12-01 | 김영환 | 반도체 소자의 금속배선 선폭 측정방법 |
| NZ503343A (en) | 1997-09-17 | 2002-09-27 | Genentech Inc | Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells |
| AU778199B2 (en) | 1999-10-29 | 2004-11-25 | Genentech Inc. | Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use |
| US6541249B2 (en) * | 1999-12-22 | 2003-04-01 | Human Genome Sciences, Inc. | Immortalized human stromal cell lines |
| US6632620B1 (en) * | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
| JP2004537999A (ja) | 2001-08-09 | 2004-12-24 | プロキュア・セラピューティクス・リミテッド | 前立腺様の腺を得るための細胞培養方法 |
| US20030119080A1 (en) | 2001-10-15 | 2003-06-26 | Mangano Joseph A. | Strategies for the identification and isolation of cancer stem cells and non-cancerous stem cells |
| CA2469204A1 (fr) | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Identification et caracterisation prospectives des cellules souches cancereuses du sein |
| ITTO20020311A1 (it) * | 2002-04-10 | 2003-10-10 | Medestea Int Spa | Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t |
| AU2003273542A1 (en) | 2002-05-31 | 2003-12-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of identifying and isolating stem cells and cancer stem cells |
| GB0406215D0 (en) * | 2004-03-19 | 2004-04-21 | Procure Therapeutics Ltd | Prostate stem cell |
-
2004
- 2004-03-19 GB GBGB0406215.4A patent/GB0406215D0/en not_active Ceased
-
2005
- 2005-03-18 GB GB0604722A patent/GB2424480B/en not_active Expired - Fee Related
- 2005-03-18 EP EP08002438A patent/EP2009097A1/fr not_active Withdrawn
- 2005-03-18 WO PCT/GB2005/001142 patent/WO2005089043A2/fr not_active Ceased
- 2005-03-18 AT AT05732870T patent/ATE465244T1/de not_active IP Right Cessation
- 2005-03-18 ES ES05732870T patent/ES2344706T3/es not_active Expired - Lifetime
- 2005-03-18 DE DE602005020750T patent/DE602005020750D1/de not_active Expired - Lifetime
- 2005-03-18 DK DK05732870.0T patent/DK1725655T3/da active
- 2005-03-18 CA CA2598879A patent/CA2598879C/fr not_active Expired - Fee Related
- 2005-03-18 US US10/593,128 patent/US8153421B2/en not_active Expired - Fee Related
- 2005-03-18 AU AU2005222660A patent/AU2005222660B2/en not_active Ceased
- 2005-03-18 JP JP2007503421A patent/JP5065885B2/ja not_active Expired - Fee Related
- 2005-03-18 EP EP05732870A patent/EP1725655B1/fr not_active Expired - Lifetime
-
2008
- 2008-04-14 JP JP2008104998A patent/JP2008283963A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2424480B (en) | 2008-08-06 |
| CA2598879A1 (fr) | 2005-09-29 |
| DE602005020750D1 (de) | 2010-06-02 |
| WO2005089043A3 (fr) | 2006-06-08 |
| AU2005222660A1 (en) | 2005-09-29 |
| AU2005222660B2 (en) | 2009-11-12 |
| JP2008283963A (ja) | 2008-11-27 |
| WO2005089043A2 (fr) | 2005-09-29 |
| ATE465244T1 (de) | 2010-05-15 |
| EP1725655B1 (fr) | 2010-04-21 |
| CA2598879C (fr) | 2014-09-09 |
| EP1725655A2 (fr) | 2006-11-29 |
| US20080233640A1 (en) | 2008-09-25 |
| JP5065885B2 (ja) | 2012-11-07 |
| GB0604722D0 (en) | 2006-04-19 |
| GB0406215D0 (en) | 2004-04-21 |
| US8153421B2 (en) | 2012-04-10 |
| GB2424480A (en) | 2006-09-27 |
| JP2007535914A (ja) | 2007-12-13 |
| EP2009097A1 (fr) | 2008-12-31 |
| ES2344706T3 (es) | 2010-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1725655T3 (da) | Cancerøse prostatastamceller | |
| WO2007008943A3 (fr) | Proteines optimisees qui ciblent la molecule ep-cam | |
| CL2007003622A1 (es) | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. | |
| PL1851250T3 (pl) | Ludzkie przeciwciało monoklonalne przeciwko antygenowi błony komórkowej komórek prostaty (PSMA) | |
| EP1599228A4 (fr) | Anticorps modifies diriges contre un antigene membranaire specifique de la prostate | |
| BRPI0607450A2 (pt) | anticorpos que se ligam a epha2 e métodos para sua utilização | |
| ATE516842T1 (de) | Intravasculärer führungsdraht | |
| MY148635A (en) | Anti-tat226 antibodies and immunoconjugates | |
| WO2008052187A3 (fr) | Anticorps et immunoconjugués, et leurs utilisations | |
| WO2008128169A8 (fr) | Sparc et procédés pour leur utilisation | |
| CU20120095A7 (es) | Antagonistas de pcsk9 | |
| NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
| IL204542A (en) | Unique monoclonal antibodies for protofibrillary form of cellulose-amyloid protein, methods and uses thereof | |
| BRPI0510674A (pt) | variantes fc otimizadas | |
| HUE058814T2 (hu) | Monoklonális antitestek a Claudin-18 ellen a rák kezelésére | |
| TW200613673A (en) | Vacuum valve | |
| NO20083593L (no) | Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse | |
| AR054597A1 (es) | Desarrollo de nuevo germoplasma empleando segregados de cruces transgenicos | |
| CA113787S (en) | Lever | |
| DE602005017877D1 (de) | Restenose-therapie mit mesenchym-stammzellen | |
| EP1766389A4 (fr) | Procede d'isolement de cellules | |
| WO2005103229A3 (fr) | Mitochondries trasngeniques, cellules et organismes transmitochondriaux et procedes de production associes | |
| IT1403844B1 (it) | Layout di impianto di produzione, particolarmente per valigie, bauli e simili. | |
| BRPI0511287A (pt) | uso de células-tronco do sangue do cordão umbilical para tratar evento isquêmico | |
| WO2010053522A3 (fr) | Procédé d'identification et de production de cellules neuronales et progénitrices souches et leur descendance |